Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

306.70 +5.67 (+1.88%)

Streaming Delayed Price Updated: 10:17 AM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

21 22 Next >

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years ↗

June 16, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 09, 2023

Via Benzinga

Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech ↗

June 07, 2023

Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by

Via Benzinga

Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference

June 05, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

May 31, 2023

Via Benzinga

Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest ↗

May 22, 2023

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for...

Via Benzinga

Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

May 20, 2023

From Alnylam

Via Business Wire

Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗

May 10, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023 ↗

May 05, 2023

Via Benzinga

$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,600 Today ↗

May 05, 2023

Via Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts ↗

May 05, 2023

Via Benzinga

Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution ↗

May 04, 2023

Via Benzinga

Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

May 04, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference

May 03, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

How To Attend Alnylam Pharmaceuticals Q1 2023 Earnings Conference Call ↗

April 21, 2023

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today ↗

April 17, 2023

Via Benzinga

A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart ↗

April 11, 2023

Via Benzinga

Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today ↗

April 05, 2023

Via Benzinga

Alnylam Issues 2022 Corporate Responsibility Report

May 03, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says ↗

April 27, 2023

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Via Benzinga

Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

April 26, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

April 26, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Why Legend Biotech Stock Is Having Its Best Month Yet

April 25, 2023

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

Via MarketBeat

3 Pharma Stocks That Could See a Surge in Demand in 2023 ↗

April 24, 2023

These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead

Via InvestorPlace

Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results

April 20, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 19, 2023

Via Benzinga

Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' ↗

April 12, 2023

SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...

Via Benzinga

Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗

April 04, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today